Últimas noticias sobre Cutera (NASDAQ:CUTR) Bolsa

Cutera

Cutera Inc is a medical device company that specializes in designing, developing, manufacturing, marketing, and servicing laser and other energy-based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States segment. Its products enable medical practitioners to perform safe procedures including treatment for acne, body contouring, skin resurfacing and revitalization, hair and tattoo removal, removal of benign pigmented lesions, and vascular conditions.

Cutera Inc

WIIM

CUTR

Cutera shares are trading lower after the company reported mixed Q3 financial results.

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

News

Guidance

Cutera Affirms FY2024 Sales Guidance to $140.00M-145.00M  VS Est.141.53M

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(0.96) by 73.96 percent. The company reported quarterly sales of $32.500 million which beat the analyst consensus estimate of $32.086 million by 1.29 percent. This is a 30.07 percent decrease over sales of $46.478 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cutera Q3 2024 Adj. EPS $(1.67) Misses $(0.96) Estimate, Sales $32.500M Beat $32.086M Estimate

<h3>Gainers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares rose 13.7% to $0.06 during Monday's after-market session. The market value of their outstanding shares is at $7.2 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 6.11% to $0.92. The company's market cap stands at $17.8 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares rose 5.64% to $14.65. The market value of their outstanding shares is at $454.9 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock moved upwards by 5.45% to $0.75. The company's market cap stands at $15.1 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 4.99% to $0.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 4.93% to $9.79. The market value of their outstanding shares is at $485.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 8.9% to $1.13 during Monday's after-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.8% to $4.14. The company's market cap stands at $5.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock declined by 5.67% to $1.5. The market value of their outstanding shares is at $11.1 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 5.07% to $0.33. The market value of their outstanding shares is at $6.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares decreased by 4.89% to $6.81. The company's market cap stands at $227.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 4.89% to $0.78. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AURA

BFRI

CTCX

DWTX

GRAL

GRTS

INVO

OGEN

SERA

12 Health Care Stocks Moving In Monday's After-Market Session

Stephens &amp; Co. analyst George Sellers maintains Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Overweight and lowers the price target from $10 to $5.

Price Target

Analyst Ratings

Stephens & Co. Maintains Overweight on Cutera, Lowers Price Target to $5

Piper Sandler analyst Matt O'Brien reiterates Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Neutral and lowers the price target from $3 to $1.

Reiteration

Piper Sandler Reiterates Neutral on Cutera, Lowers Price Target to $1

Cutera shares are trading lower after the company reported worse-than-expected Q2 revenue results and cut its FY24 revenue guidance.

Shares of Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) rose sharply in today's pre-market trading reported better-than-expected first-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/08/40269788/doximity-stock-soars-on-q1-earnings-the-details">strong FY24 revenue guidance.</a>
Doximity's first-quarter revenue increased 17% year-over-year to $126.68 million, beating the consensus estimate of $119.92 million, according to Benzinga Pro. The company reported adjusted earnings of 28 cents per share, beating analyst estimates of 22 cents per share.
Doximity shares jumped 28.6% to $33.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Iteris, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NASDAQ">ITI</a>) rose 61.7% to $6.92 in today's pre-market trading after the company agreed to be acquired by Almaviva for $335 million.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 53% to $0.14 in pre-market trading after gaining 16% on Thursday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 45.8% to $2.80 in pre-market trading. Nauticus Robotics partnered with Florida Atlantic University for cost-effective Aquanaut Mark 2 testing.</li>
<li>Avinger, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 28.3% to $1.54 in pre-market trading after reporting second-quarter results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 27.7% to $10.14 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued Q3 product revenue guidance above estimates.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) shares gained 27.7% to $1.52 in pre-market trading after declining around 8% on Thursday.</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) gained 27.1% to $2.30 in pre-market trading after the company announced AI-powered tool enhancements to its integrations with Reddit and X.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) gained 22.5% to $1.36 following second-quarter results.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) jumped 22.3% to $32.11 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) shares dipped 30.8% to $5.66 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>PubMatic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) shares declined 26.4% to $14.40 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Cutera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares declined 21.4% to $0.88 in pre-market trading after the company reported worse-than-expected second-quarter revenue results and cut its FY24 revenue guidance below estimates.</li>
<li>Nerdy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) declined 20.1% to $1.27 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>FiscalNote Holdings, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) shares fell 18.3% to $1.12 in pre-market trading after reporting second-quarter results.</li>
<li>Eventbrite, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) fell 17.1% to $3.15 in today's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued FY24 revenue guidance below estimates.</li>
<li>AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares fell 16.7% to $1.35 in pre-market trading after the company reported weak first-quarter sales.</li>
<li>Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) fell 16.4% to $35.49 in pre-market trading after the company posted second-quarter results.</li>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) fell 14.7% to $0.19 pre-market trading after the company reported second-quarter results.</li>
<li>Anew Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WENA#NASDAQ">WENA</a>) shares fell 10.1% to $1.15 in pre-market trading after gaining 17% on Thursday.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Pre-Market Outlook

Markets

Trading Ideas

AVGR

CMND

DOCS

FIVN

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

IOVA

KITT

MRIN

NOTE

NRDY

POWW

PUBM

TRVN

WENA

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Cutera Says Q2 Restructuring Resulted In $20M In Expense Savings On An Annualized Basis

Cutera shares are trading lower after the company reported worse-than-expected Q2 revenue results and cut its FY24 revenue guidance below estimates.

Cutera Sees FY24 Revenue $140M-$145M vs $161.81M Est. (Prior Outlook $160M-$170M)

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly sales of $34.400 million which missed the analyst consensus estimate of $38.695 million by 11.10 percent. This is a 43.81 percent decrease over sales of $61.218 million the same period last year.

Cutera Q2 Sales $34.400M Miss $38.695M Estimate

Cutera Announces Partnership With L'Oréal Japan To Exclusively Promote, Market, Sell And Distribute SkinCeuticals To Clinics In Japan

Stephens &amp; Co. analyst George Sellers reiterates Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Overweight and maintains $10 price target.

Stephens & Co. Reiterates Overweight on Cutera, Maintains $10 Price Target

Piper Sandler analyst Matt O'Brien maintains Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Neutral and maintains $3 price target.

Piper Sandler Maintains Neutral on Cutera, Maintains $3 Price Target

Cutera Reaches Settlement Agreement With Lutronic Aesthetics Regarding All Litigation And Arbitration Matters; Lutronic To Pay $5.75M Within 30 Days

Cutera Reiterates FY24 Revenue $160M-$170M Vs $162.874M

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(1.00) by 9 percent. This is a 13.49 percent increase over losses of $(1.26) per share from the same period last year. The company reported quarterly sales of $38.793 million which beat the analyst consensus estimate of $37.325 million by 3.93 percent. This is a 28.85 percent decrease over sales of $54.526 million the same period last year.

Cutera Q1 2024 Adj EPS $(1.09) Misses $(1.00) Estimate, Sales $38.793M Beat $37.325M Estimate

<h3>Gainers</h3>
<ul>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) shares moved upwards by 75.9% to $1.39 during Tuesday's after-market session. The market value of their outstanding shares is at $44.8 million. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares rose 43.48% to $0.49. The market value of their outstanding shares is at $23.1 million. </li>
<li>Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) shares rose 20.77% to $6.57. The market value of their outstanding shares is at $325.5 million. </li>
<li>Inspire Veterinary (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) stock increased by 16.59% to $0.05. The market value of their outstanding shares is at $1.7 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 6.41% to $3.15. The market value of their outstanding shares is at $203.0 million. As per the news, the Q4 earnings report came out 4 days ago. </li>
<li>Bionomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNOX#NASDAQ">BNOX</a>) stock rose 6.01% to $1.05. The market value of their outstanding shares is at $11.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) stock decreased by 14.1% to $0.98 during Tuesday's after-market session. The market value of their outstanding shares is at $7.1 million. </li>
<li>Acorda Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACOR#NASDAQ">ACOR</a>) stock fell 12.0% to $2.2. The market value of their outstanding shares is at $2.7 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares declined by 7.43% to $1.62. The market value of their outstanding shares is at $15.2 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares decreased by 6.55% to $1.0. The market value of their outstanding shares is at $14.7 million. As per the press release, Q4 earnings came out yesterday. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 6.17% to $1.37. The market value of their outstanding shares is at $39.3 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares decreased by 4.9% to $1.36. The market value of their outstanding shares is at $27.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACOR

BNOX

CYTH

ENVB

GLYC

IMNN

MIRA

ONMD

SGHT

12 Health Care Stocks Moving In Tuesday's After-Market Session

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining around 0.3% on Friday.
The Dow traded down 0.49% to 39,585.67 while the NASDAQ rose 0.26% to 16,444.91. The S&amp;P 500 also rose, gaining, 0.01% to 5,241.56.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37889054/these-3-risk-off-stocks-with-over-3-dividend-yields-are-recommended-by-wall-streets-most"> These 3 Risk Off Stocks With Over 3% Dividend Yields Are Recommended By Wall Street&#39;s Most Accurate Analysts</a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Communication services shares jumped by 0.8% on Friday.
In trading on Friday, real estate shares fell by 1.1%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Shares of Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) fell more than 15% during Friday&rsquo;s session after releasing fourth-quarter results.
Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter.
The company said it sees first-quarter revenue in the range of $2.175 billion to $2.2 billion versus estimates of $2.25 billion. The company anticipates first-quarter earnings of $2.35 to $2.40 per share versus estimates of $2.55 per share, according to data from Benzinga Pro.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Summit Midstream Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smlp#NYSE">SMLP</a>) shares shot up 38% to $26.85 after the company announced the sale of its Utica position for $625 million.
Shares of Outlook Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/otlk#NASDAQ">OTLK</a>) got a boost, surging 19% to $8.40 after the company announced it received a positive European Union CHMP opinion for ONS-5010 as a treatment for Wet AMD.
Intellicheck, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/idn#NASDAQ">IDN</a>) shares were also up, gaining 70% to $2.98 after the company reported a year-over-year increase in fourth-quarter EPS results.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Cutera, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cutr#NASDAQ">CUTR</a>) shares dropped 29% to $1.6391 after the company reported worse-than-expected fourth quarter adjusted EPS results.
Shares of Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) were down 31% to $0.0941 after the company announced a proposed public offering of common stock.
Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) was down, falling 26% to $5.97 after the company announced the pricing of its public offering of 2.05 million shares of common stock at $6.00 per share.
Also Check This Out:<a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37889060/top-3-materials-stocks-that-could-blast-off-in-q1"> Top 3 Materials Stocks That Could Blast Off In Q1</a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded down 0.5% to $80.63 while gold traded down 0.9% at $2,164.20.
Silver traded down 0.6% to $24.85 on Friday, while copper fell 1.2% to $4.0090.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were mixed today. The eurozone&rsquo;s STOXX 600 fell 0.03%, London&rsquo;s FTSE 100 jumped 0.61% while Spain&rsquo;s IBEX 35 Index rose 0.70% The German DAX rose 0.15% French CAC 40 fell 0.34% while Italy&rsquo;s FTSE MIB Index rose 0.05%.
The Ifo Business Climate indicator for Germany climbed to 87.8 in March from February&#39;s revised reading of 85.7. German import prices declined 5.9% year-over-year in January.
Retail sales volumes in the UK came in unchanged for February, while UK&rsquo;s GfK Consumer Confidence indicator came in flat at -21 in March.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mixed on Friday, with Japan&rsquo;s Nikkei 225 gaining 0.18%, Hong Kong&rsquo;s Hang Seng Index falling 2.16%, China&rsquo;s Shanghai Composite Index falling 0.95% and India&rsquo;s S&amp;P BSE Sensex gaining 0.26%.
Foreign direct investment into China dipped by 19.9% year-over-year to CNY 215.1 billion during the first two months of the year. The annual inflation rate in Japan accelerated to 2.8% in February from 2.2% a month ago.
&nbsp;
<h3>Economics</h3>
&nbsp;
The total number of active U.S. oil rigs fell by 1 rig this week, Baker Hughes Inc reported.
Now Read This: <a href="https://www.benzinga.com/author/avi-kapoor-vedainformatics-com"> Around $5M Bet On This Communication Services Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

ISPR

LULU

OTLK

SINT

SMLP

Gold Moves Lower; Lululemon Shares Plummet

Piper Sandler Sticks to Their Hold Rating for Cutera (CUTR)

Maxim Group analyst Anthony Vendetti has maintained their neutral stance on CUTR stock, giving a Hold rating yesterday. Anthony Vendetti has given ...

Cutera's Hold Rating Affirmed Amid Financial Challenges and Operational Headwinds

Cutera, Inc (CUTR) Q2 2024 Earnings Call Transcript

An announcement from Cutera ( ($CUTR) ) is now available. Cutera, Inc. faces a challenge as its stock price has fallen below Nasdaq's minimum requi...

Cutera Navigates Stock Woes and CTO Departure

InMode: A Deep Dive After Q3 Earnings

Reports Q3 revenue $32.5M, consensus $32.09M. "Our third quarter reflects consistent execution against our strategic priorities, with core capital ...

Cutera reports Q3 EPS ($1.94) vs. ($2.22) last year

Management is reaffirming full-year revenue guidance of $140 million to $145 million, as well as guidance for year-end 2024 cash, cash equivalents ...

Cutera sees FY24 revenue $140M-$145M, consensus $141.53M

Stifel Nicolaus analyst Jonathan Block maintained a Buy rating on Cutera (CUTR – Research Report) today and set a price target of $2.00. The compan...

Cutera (CUTR) Gets a Buy from Stifel Nicolaus

In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Cutera (CUTR – Research Report). The company's shares...

Cutera (CUTR) Receives a Hold from Maxim Group

Cutera, Inc. (CUTR) Q3 2024 Earnings Call Transcript

AIRS

APYX

INMD

RVNC

Press Releases

Cutera, Inc. Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

Cutera® Announces AviClear® Investor Webinar

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Cutera® Announces New Survey Data During Acne Awareness Month

Cutera® to Announce Second Quarter Results on August 8, 2024

Cutera® Announces Exclusive Distribution Agreement With L'Oréal® for SkinCeuticals® Products in Japan

Comments

Cutera

Noticias

Últimas noticias sobre Cutera (NASDAQ:CUTR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL